Komori
Changes in Officers4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Election of Directors and Executive Officers, etc.

At the 21st Annual General Meeting of Shareholders, directors and an alternate director serving as an Audit and Supervisory Committee member were elected, and the Representative Directors and Executive Officers were subsequently determined at meetings of the Board of Directors and other bodies. The Company will have 8 directors, a majority of whom will be outside directors.

Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 24 March 2026

Incoming appointee

4 items
Nomura Hiroshi (野村 博)
New positionOutside Director
Mizutani Eiji (水谷 英滋)
New positionDirector and Audit & Supervisory Committee Member (Outside)
Ichinosawa Tsuyoshi (市野澤 剛士)
New positionDirector and Audit & Supervisory Committee Member (Outside)
Endo Kesao (遠藤 今朝夫)
New positionAlternate Director serving as an Audit and Supervisory Committee Member (Outside)
Directors after the change8Number
Shareholders’ meeting approvalThe election of directors (excluding directors serving as Audit and Supervisory Committee members), directors serving as Audit and Supervisory Committee members, and alternate directors serving as Audit and Supervisory Committee members has already been approved by resolution at the 21st Annual General Meeting of Shareholders. The scheduled meeting date is Not disclosed
Who is moving to which position
ItemDetails
Resolution date24 March 2026
Name of appointeeNomura Hiroshi (野村 博), Mizutani Eiji (水谷 英滋), Ichinosawa Tsuyoshi (市野澤 剛士), Endo Kesao (遠藤 今朝夫)
Appointee's new positionOutside Director, Director and Audit & Supervisory Committee Member (Outside), Director and Audit & Supervisory Committee Member (Outside), Alternate Director serving as an Audit and Supervisory Committee Member (Outside)
Number of directors after the change8, including 7 outside directors
Subject to Approval by the General Meeting of ShareholdersThe election of directors (excluding directors serving as Audit and Supervisory Committee members), directors serving as Audit and Supervisory Committee members, and alternate directors serving as Audit and Supervisory Committee members has already been approved by resolution at the 21st Annual General Meeting of Shareholders. The scheduled meeting date is Not disclosed
Items this document does not state (16)
Scheduled Appointment DateDate of departureAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reason for the personnel change is not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Election of Directors and Executive Officers, etc. | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori